Session Abstract – PMWC 2027 Silicon Valley
Speaker Profile
Biography
Arie S. Belldegrun is a trail‑blazing urologic‑oncologist‑turned‑biotech entrepreneur whose company‑building spree—from Agensys and Cougar to Kite Pharma—helped usher in the first FDA‑approved CAR‑T therapy and led to Kite’s $11.9 billion sale to Gilead Sciences. After that landmark exit, he co‑founded Allogene Therapeutics and still serves as its Executive Chairman, steering the next wave of off‑the‑shelf (allogeneic) CAR‑T cell products toward the clinic. Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the real‑estate venture Breakthrough Properties, nurturing a constellation of startups that translate science into patient impact. Over three decades on UCLA’s faculty, he has authored 500‑plus scientific papers, mentored a generation of physician‑scientists, and kept patient benefit at the center of every deal—cementing his reputation as one of precision medicine’s most influential builders.
Speaker Profile
Biography
Dr. Kiran Khush is an advanced heart failure and transplant cardiologist at Stanford University. She is a clinical and translational investigator who runs a wide-ranging research program related to (1) evidence-based evaluation and selection of donors for heart transplantation, (2) pathogenesis of primary graft dysfunction after heart transplantation, and (3) development and testing of novel genomic biomarkers for heart transplant surveillance. Dr. Khush is the program director of the advanced heart failure transplant cardiology fellowship at Stanford and was the Program Chair of the 2025 annual meeting of the International Society for Heart and Lung Transplantation (ISHLT). She is the President-Elect of the ISHLT.
Speaker Profile
Biography
Dr. Sadovsky is the Executive Director of Magee Women's Research Institute, the Elsie Hilliard Hillman Chair of Women's Health Research, Distinguished Professor of OBGYN, Microbiology and Molecular Genetics, and Associate Dean, Women's Health Research and Reproductive Sciences, University of Pittsburgh. He is board certified in obstetrics and gynecology (Washington University), and maternal-fetal medicine (UCSF). His NIH-funded research focuses on feto-placental development and molecular mechanisms underlying placental function, aiming to better understand early human development and pregnancy health. He is a member of the National Academy of Medicine and the Association of American Physicians. He has served as president of the Society for Reproductive Investigation, on the Councils for NIHNICHD and the March of Dimes, and currently serves on the NIH Advisory Committee on Research in Womens Health. In 2013, he was awarded the Cozzarelli Prize in Biomedical Science from the National Academy of Sciences.
Speaker Profile
Biography
Iwijn De Vlaminck trained in applied physics (Ph.D., KULeuven), single molecule biophysics (postdoc, TUDelft) and precision medicine (HHMI research associate, Stanford University). His most recent research has led to the development of sensitive blood tests to diagnose organ transplant rejection, already widely used, the Karius blood test to screen for infection from blood, used in more than 400 US hospitals, RNA liquid biopsy technologies to monitor inflammatory disease, technologies to spatially map RNA in tissues, and highly multiplexed imaging methods to map the biogeography of the human microbiome. He is an elected fellow of the American Institute of Medical and Biological Engineering and a recipient of the NIH New Innovator and NIH MERIT awards. He is a co-founder of Kanvas Biosciences and Romix Biosciences.
Speaker Profile
Biography
Charles Chiu, M.D. Ph.D. is a Professor at UCSF, Director of the UCS-FAbbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. Chiu currently leads a translational research laboratory focused on clinical metagenomic sequencing assay development for infectious diseases and genomic investigation and surveillance of emerging pathogens, including the SARSCoV2 coronavirus. He also uses RNASeq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of COVID19 and other infections. Chius work is supported by funding from the National Institutes of Health (NIH), Department of Defense, US Centers for Disease Control and Prevention (CDC), philanthropy, and the California Initiative to Advance Precision Medicine. He has authored more than 100 peer reviewed publications (20 on COVID19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Danaher Dx, Biomesense, and Flightpath.
Speaker Profile
Biography
Dr. Joe DeRisi is a professor of biochemistry and biophysics at UCSF and President at the Chan Zuckerberg Biohub SF, a nonprofit research institute affiliated with UCSF, UCB, and Stanford. Dr. DeRisi specializes in infectious diseases, including viral, fungal, and parasitic microbes, in addition to autoimmune syndromes in humans. He is a member of the NAS, the NAM, and the American Academy of Arts and Sciences.
Speaker Profile
Biography
Dr. Minnie M. Sarwal is an adult and pediatric trained transplant nephrologist who heads the kidney pancreas transplant program at UCSF for transplantation of patients with Type 1 Diabetes and renal failure. She has spearheaded new diagnostics for precision medicine to personalize diagnosis of transplant rejection. Her lab has been consecutively funded by the NIH for 30 yrs and leads in computational drug repuprosing and population scale EHR analysis to improve outcomes for chronic disease.
Sarwal is trained in India and the UK, competing her MD in India and advanced cliical training at Guys Hospital, London and Addenbrooke's Hospital in Cambridge. She earned her doctorate in molecular genetics at the University of Cambridge under her mentor Nobel Laureate Sydney Brenner.
Sarwal is an exited enterpreneur from Stanford and continues to do pivotal work to produce commercially available tests and new compunds for organ transplant rejection and chronic mutli-organ disease
Speaker Profile
Biography
Dr. Joe DeRisi is a professor of biochemistry and biophysics at UCSF and President at the Chan Zuckerberg Biohub SF, a nonprofit research institute affiliated with UCSF, UCB, and Stanford. Dr. DeRisi specializes in infectious diseases, including viral, fungal, and parasitic microbes, in addition to autoimmune syndromes in humans. He is a member of the NAS, the NAM, and the American Academy of Arts and Sciences.
Speaker Profile
Biography
Duncan MacCannell is the Director of the Office of Advanced Molecular Detection (OAMD) at the
Centers for Disease Control and Prevention (CDC), where he leads efforts to build, integrate and sustain pathogen genomics, metagenomics, bioinformatics and scientific computing capabilities across the U.S. public health system. OAMD supports all of CDC’s infectious disease programs, state and local health departments, and a growing network of global public health, academic and private sector partners. Dr. MacCannell’s current priorities include pathogen-agnostic and metagenomic biosurveillance, with standardized, reproducible bioinformatic workflows and regulatory-ready quality frameworks; the responsible use of AI in public health and biosecurity; and resilient, local sequencing and analytic capacity tied to meaningful public health action.
Speaker Profile
Biography
Bruce Quinn MD PhD is an expert on health reform, innovation, and Medicare policy. A pathologist by training, he has worked on a wide range of federal health policy issues ranging from biopharma to genomics. After a career in academic medicine, he became a successful physician executive at Accenture, serving clients in both the biopharma and payer industries. For five years, he was the regional Medicare medical director for California, making decisions on a wide range of emerging technologies. Since 2008, he has been a full time life sciences strategy consultant at several major Washington-based policy firms. Since 2017, Dr. Quinn manages his own medtech and biopharma consulting practice based in Los Angeles and San Francisco, Bruce Quinn Associates LLC.
Speaker Profile
Biography
Independent investigator with an active research laboratory for >25 years, focusing on discovering pathogenic pathways and bringing therapies to patients in the areas of hypertensive disorders of pregnancy and kidney diseases
Research activities are vertically integrated, ranging from molecular and cell biological studies to animal models, epidemiological studies and frist-in-class human clinical trials
>350 publications (H index =133) & research supported by HHMI, NIH, AHA, Gates foundation and industry; 15 issued patents in biomedicine
Co-director of NIH training grant for Kidney, Urology and Hematology at UCLA/Cedars-Sinai
Received multiple scientific recognition awards (Established Investigator Award - AHA, Chesley Award - International Society for the Study of Hypertension in Pregnancy, Outstanding Investigator Award - American Federation of Medical Research, Jean Hamburger Prize- ISN)
Inducted to American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP)
Trained >50 graduate and post-doctoral fellows in basic and translational research.
Associate Editor-Hypertension and Editorial board of numerous medical Journals (JCI, JASN, Hypertension in Pregnancy)
12 endowed lectureships and > 200 invited lectures throughout the world
Speaker Profile
Biography
Dr. Langelier seeks to advance the understanding and management of pneumonia, sepsis, and other infectious and inflammatory diseases through clinical investigation that harnesses multi-omic technologies. His research spans three central areas: developing novel molecular diagnostics for infectious diseases, studying the host/pathogen biology of pneumonia and sepsis, and improving methods for the surveillance of emerging infections. Among his significant contributions is the development of novel culture-independent diagnostics for pneumonia and sepsis that integrate host gene expression profiling, unbiased pathogen detection, and microbiome profiling. More recently, his lab has applied multi-omic approaches that assess both host and microbe to investigate the biology of pneumonia, sepsis and ARDS. Dr. Langelier has additionally drawn on expertise in microbial genomics to lead a genomic epidemiology service for UCSF hospitals, develop new methods for tracking antimicrobial-resistant microbes, and deploy culture-independent metagenomics for emerging pathogen surveillance.
Speaker Profile
Biography
Gabriel Bien-Willner, MD, PhD, is Executive Chairman of Bien-Willner Physicians Group, PA, a medical services organization providing consulting, clinical services, and molecular diagnostics through a CAP/CLIA-accredited laboratory.
Previously, he served as Chief Medical Officer at Palmetto GBA, where he led the MolDX program, shaping Medicare coverage, reimbursement, and evidence standards for innovative molecular diagnostic tests. He also led the development of DEX, a platform extending molecular diagnostic identification and claims management tools to commercial payers.
A board-certified anatomic and molecular genetic pathologist, Dr. Bien-Willner earned his MD and PhD in Human Molecular Genetics from Baylor College of Medicine and completed his clinical training at Washington University in St. Louis. His career spans molecular diagnostics, precision medicine, and healthcare policy.
Speaker Profile
Biography
Maarten Naesens, M.D., Ph.D., is Professor at KU Leuven and a transplant physician-scientist focused on improving long-term outcomes after kidney transplantation. His research combines clinical data, tissue pathology, molecular profiling, and computational approaches to understand why transplanted kidneys fail and how rejection can be detected and treated more precisely. His group studies the biology of alloimmune injury, chronic graft damage, and treatment response using transcriptomics, single-cell and spatial technologies, circulating biomarkers, and cell-free DNA. Dr. Naesens is also involved in efforts to integrate these data into clinical decision-support tools that can move transplant care beyond conventional histology and one-size-fits-all immunosuppression. Through KU Leuven and University Hospitals Leuven, he has contributed to large translational cohorts linking molecular findings with longitudinal patient outcomes. His work aims to define actionable disease states, identify earlier signals of rejection or injury, and develop precision strategies that preserve graft function while minimizing unnecessary immunosuppression and treatment toxicity.
Speaker Profile
Biography
Dawn Cardeiro, M.S., is a Market Access Strategy Director at Roche Diagnostics, where she develops U.S. strategies to advance patient access to innovative diagnostics. Her career spans over three decades in clinical, advocacy, and commercial roles in precision medicine, including positions at North Central Bronx Hospital, Baystate Medical Center, Point32Health, Myriad Genetics, and Foundation Medicine.
Dedicated to shaping payer policy and expanding access to diagnostics, Dawn serves on the board of the Access to Comprehensive Genomic Profiling Coalition (ACGP) and previously served on the board of directors for the Personalized Medicine Coalition (PMC).
She holds a B.S. in Chemistry from Fairfield University and an M.S. in Human Genetics from Sarah Lawrence College, where she trained as a genetic counselor. By combining her clinical roots and deep technical foundation with extensive industry expertise, Dawn effectively navigates complex health systems to improve patient outcomes.
Speaker Profile
Biography
John Hanna has more than two decades of executive leadership experience and has helped advance CareDx into a precision diagnostics company focused on transplant, specialty oncology, and cell therapy, combining molecular testing, clinical evidence generation, digital solutions, and patient support services to improve patient outcomes.
Prior to joining CareDx, he served as Chief Executive Officer of Apton Biosystems, where he led development of a high-throughput next-generation sequencing platform for liquid biopsy and other clinical applications. Following Apton's acquisition by Pacific Biosciences in 2023, he served as Vice President of Corporate Development. Previously, John spent a decade at Veracyte, an oncology diagnostics company, where he held several leadership roles, including Chief Commercial Officer and Vice President of Marketing. Earlier in his career, he held leadership positions at Humana and IBM. John earned a B.S. in Political Science from Hampden-Sydney College and an MBA from the University of Miami.
Talk
Precision Medicine's Real Challenge: Turning Insight into Clinical Action
Precision medicine's next frontier isn't generating more insight, it's acting on it. John Hanna explores how combining clinical and molecular data with AI-driven models is enabling longitudinal and personalized care. He'll examine what it takes, from data science to operational execution, to close that gap and turn insight into meaningful shifts in patient care.
Speaker Profile
Biography
Alexandre Loupy is an internationally recognized physician-scientist who has transformed how transplant rejection and long-term graft survival are characterized and predicted. He is at the head of the Paris Institute for Transplantation & Organ Regeneration, where he has built large, deeply characterized cohorts integrating clinical, biological, immunologic, histologic, and transcriptomic data. He led the development of iBox, a prediction system that combines kidney function, proteinuria, donor-specific antibodies, and biopsy findings to estimate an individual patient's risk of kidney-allograft loss. The system was developed and validated in 7,557 recipients across 10 centers in Europe and North America and confirmed in three randomized clinical trials. It has received regulatory qualification in Europe and a favorable FDA qualification opinion for transplant clinical trials. Loupy has also applied machine learning and molecular profiling to identify distinct rejection phenotypes and improve transplant diagnostics. His work extends beyond kidney transplantation to heart-transplant rejection and pig-to-human xenotransplantation.
Speaker Profile
Biography
Alexandre Loupy is an internationally recognized physician-scientist who has transformed how transplant rejection and long-term graft survival are characterized and predicted. He is at the head of the Paris Institute for Transplantation & Organ Regeneration, where he has built large, deeply characterized cohorts integrating clinical, biological, immunologic, histologic, and transcriptomic data. He led the development of iBox, a prediction system that combines kidney function, proteinuria, donor-specific antibodies, and biopsy findings to estimate an individual patient's risk of kidney-allograft loss. The system was developed and validated in 7,557 recipients across 10 centers in Europe and North America and confirmed in three randomized clinical trials. It has received regulatory qualification in Europe and a favorable FDA qualification opinion for transplant clinical trials. Loupy has also applied machine learning and molecular profiling to identify distinct rejection phenotypes and improve transplant diagnostics. His work extends beyond kidney transplantation to heart-transplant rejection and pig-to-human xenotransplantation.
Speaker Profile
Biography
Stacey Brown is a healthcare market-access executive with more than 20 years of experience in reimbursement, payer strategy, provider engagement, evidence, and commercialization. She serves as Americas Market Access Lead at Cepheid, where her work supports adoption of molecular diagnostic technologies across complex U.S. healthcare and payment environments. She is also founder and president of Arduous Access Solutions. Ms. Brown previously held market-access and evidence leadership roles at Optum Life Sciences and served as Vice President of Market Access and Channel Innovations at GeneDx. Earlier, she worked in market-access roles at Foundation Medicine, gaining experience with precision oncology, genomic testing, reimbursement pathways, and the evidence needed to support clinical adoption. She earned a bachelor’s degree in microbiology from the University of Montana. Across diagnostics and precision medicine, her work focuses on translating clinical value into practical access, aligning evidence generation with payer requirements, and reducing reimbursement barriers that can prevent validated tests from reaching patients.
Speaker Profile
Biography
Michael Snyder is the Stanford W. Ascherman Professor and the Director of the Stanford Center of Genomics and Personalized Medicine. As a pioneer of Precision Medicine, Dr. Snyder has invented many technologies enabling the 21st century of healthcare including systems biology, RNA sequencing, and protein chip. Dr. Snyder has initiated the Big Data approach to healthcare through his work using omics to detect early-stage disease, including wearables to detect infectious diseases like COVID-19, and at-home microsampling to measure hundreds of molecules from a single drop of blood. He is the first researcher to gather petabytes of data on individuals, which is 1 million - 1 trillion times more data than the average clinician collects. He has published over 900 papers and is one of the most cited scientists. In terms of commercial success, Dr. Snyder has co-founded 17 companies (including 2 unicorns) with combined enterprise value of over $6 billion.
Speaker Profile
Biography
Sivan is a recognized innovator and entrepreneur in artificial intelligence who has dedicated two decades to pioneering the development of complex computational and data platforms. His key contributions include the development of novel machine-learning models tackling significant challenges in human disease. At Karius, he spearheaded the development of the foundational computational platform underlying the Karius Test, elevated the biomarker discovery program, and was central to forming and nurturing key strategic partnerships, furthering the companys impact in the medical field. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode, where he led the development of the analytical platform and validation of several clinical assays across oncology and rare diseases. He holds a Ph.D. in Computer Science from the Technion Israel Institute of Technology, and continued to Stanfords Artificial Intelligence Lab to pursue his post-doctoral research.
Speaker Profile
Biography
Sivan is a recognized innovator and entrepreneur in artificial intelligence who has dedicated two decades to pioneering the development of complex computational and data platforms. His key contributions include the development of novel machine-learning models tackling significant challenges in human disease. At Karius, he spearheaded the development of the foundational computational platform underlying the Karius Test, elevated the biomarker discovery program, and was central to forming and nurturing key strategic partnerships, furthering the companys impact in the medical field. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode, where he led the development of the analytical platform and validation of several clinical assays across oncology and rare diseases. He holds a Ph.D. in Computer Science from the Technion Israel Institute of Technology, and continued to Stanfords Artificial Intelligence Lab to pursue his post-doctoral research.
Speaker Profile
Biography
Stephanie L. Gaw, MD, PhD, is an Associate Professor of Obstetrics, Gynecology and Reproductive Sciences at UCSF and a maternal-fetal medicine physician-scientist. She leads the Gaw Lab, investigating how infectious diseases and immune responses during pregnancy affect placental function, fetal development, and birth outcomes. Her research focuses on maternal-fetal immunology, placental biology, and infections including malaria, COVID-19, and syphilis. Dr. Gaw earned her MD and PhD in Microbiology and Immunology at Albert Einstein College of Medicine, completed her residency at UCSF, and a maternal-fetal medicine fellowship at UCLA. She has served on advisory panels for the WHO, CDC, and NIH addressing infectious diseases in pregnancy.
Speaker Profile
Biography
Noël Pugh, PhD, JD, MHA, is Co-Founder and CEO of Lōvu Health, a maternal healthcare technology company focused on improving pregnancy and postpartum outcomes through connected, personalized care.
Lōvu combines AI-powered insights, remote patient monitoring, and care navigation to help clinicians identify pregnancy complications earlier and coordinate support beyond traditional medical visits. Previously, Pugh held leadership positions in healthcare strategy and commercialization, including roles at Medneon and MEDNAX.
Under her leadership, Lōvu secured $8 million in Series A funding in 2025 to expand its technology-enabled maternal care model. Her work focuses on improving access, aligning healthcare incentives, and integrating real-time patient data into clinical decision-making to support healthier mothers and babies.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
Day 1 / Wed · Jan 27
Day 2 / Thu · Jan 28
Day 3 / Fri · Jan 29
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
